## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.9% below STRENGTH zone (3.0-6.0%); PEG 1.09 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($108.92)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. DaVita HealthCare stock hits 52-week low at $113.96 By Investing.com**
- Source: Investing.com Canada | 20251224T150425 | Somewhat-Bearish | Relevance: 100%
- DaVita HealthCare stock has fallen to a new 52-week low of $113.96, marking a 26.24% decrease over the past year. Despite this, InvestingPro data indicates aggressive share buybacks, a strong free cash flow yield of 16%, and an undervalued status based on its P/E ratio of 11.79 and "GREAT" financial health. The company recently missed Q3 2025 earnings expectations but UBS maintained a Buy rating with a $186 price target.

**2. DaVita HealthCare stock hits 52-week low at $113.96**
- Source: Investing.com | 20251225T110849 | Somewhat-Bearish | Relevance: 98%
- DaVita HealthCare Partners Inc. (NYSE:DVA) stock has fallen to a new 52-week low of $113.96, marking a 26.24% decrease over the past year. Despite this, InvestingPro data suggests the company is undervalued, with management aggressively buying back shares, a strong free cash flow yield of 16%, a P/E ratio of 11.79, and an overall "GREAT" financial health rating. The company recently reported a miss on Q3 2025 earnings and a slight revenue shortfall, while UBS maintained a Buy rating with a $186 price target based on long-term operating income growth expectations.

**3. European markets close mixed; Novo Nordisk shares jump 9%, extending rally after GLP-1 pill approval**
- Source: CNBC | 20251224T021000 | Bullish | Relevance: 87%
- European markets closed mixed on Wednesday during a shortened Christmas Eve trading session, with the pan-European Stoxx 600 finishing just below the flatline. Novo Nordisk shares climbed 9.2% after gaining FDA approval for the first-ever GLP-1 pill, contributing to Tuesday's record close for the Stoxx 600. Sanofi's shares dipped after announcing the acquisition of Dynavax, while Puma's stock fell 1.6% amidst takeover rumors and a significant year-to-date decline.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($54.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $55M sold (3 transactions in 90 days).
2. High short interest (21.1%, 7.3 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 15.4% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.09 suggests fair value with growth premium. Forward P/E 8.9x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($55.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.1B |
| Beta | 0.99 |
| 52W Range | $113.12 - $179.60 |
| Short Interest | 21.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.09 |
| Forward P/E | 8.9 |
| Current P/E | 10.7 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -2.7% to -3.9% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.9pp (needs >3.0% for momentum thesis). Underperforming sector by 4.4pp, stock-specific weakness. Below SMA200 (0.85x), long-term trend not supportive. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.89% (CS: 6) | Weak |
| RSI_14 | 36.6 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 0.945x | Below |
| vs SMA200 | 0.846x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $113.98
- **Stop Loss:** $108.92 (4.4% risk)
- **Target:** $119.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 260
- **Position Value:** $29,634.80
- **Portfolio %:** 29.63%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*